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Abstract
Background: Expression of neuronal elements has been identified in various glial tumors, and glioblastomas
(GBMs) with neuronal differentiation patterns have reportedly been associated with longer survival. However, the
neuronal class III b-tubulin has been linked to increasing malignancy in astrocytomas. Thus, the significance of
neuronal markers in gliomas is not established.
Methods: The expressions of class III b-tubulin, neurofilament protein (NFP), microtubule-associated protein 2
(MAP2) and neuron-specific enolase (NSE) were investigated in five GBM cell lines and two GBM biopsies with
immunocytochemistry and Western blot. Moreover, the expression levels were quantified by real-time qPCR under
different culture conditions. Following NSE siRNA treatment we used Electric cell-substrate impedance sensing
(ECIS) to monitor cell growth and migration and MTS assays to study viability after irradiation and temozolomide
treatment. Finally, we quantitated NSE expression in a series of human glioma biopsies with immunohistochemistry
using a morphometry software, and collected survival data for the corresponding patients. The biopsies were then
grouped according to expression in two halves which were compared by survival analysis.
Results: Immunocytochemistry and Western blotting showed that all markers except NFP were expressed both in
GBM cell lines and biopsies. Notably, qPCR demonstrated that NSE was upregulated in cellular stress conditions,
such as serum-starvation and hypoxia, while we found no uniform pattern for the other markers. NSE knockdown
reduced the migration of glioma cells, sensitized them to hypoxia, radio- and chemotherapy. Furthermore, we
found that GBM patients in the group with the highest NSE expression lived significantly shorter than patients in
the low-expression group.
Conclusions: Neuronal markers are aberrantly expressed in human GBMs, and NSE is consistently upregulated in
different cellular stress conditions. Knockdown of NSE reduces the migration of GBM cells and sensitizes them to
hypoxia, radiotherapy and chemotherapy. In addition, GBM patients with high NSE expression had significantly
shorter survival than patients with low NSE expression. Collectively, these data suggest a role for NSE in the
adaption to cellular stress, such as during treatment.
Background
Most primary brain tumors are classified as gliomas
based on the tumor cells’ resemblance with glial cell
types and immunohistochemical characteristics, particu-
larly the expression of glial fibrillary acidic protein [1,2].
However, the cellular origin of gliomas is still controver-
sial [3,4] and the term “glioneuronal tumor” refers to
gliomas which contain neuronal elements such as neu-
rocytes or ganglion cells. In addition, several neuronal
antigens have been detected in glioblastoma multiforme
(GBM) [5-7], diffuse astrocytomas [8,9], pleomorphic
xanthoastrocytomas [10], oligodendrogliomas [11] and
ependymomas [12]. Expression of neurofilament protein
(NFP) and microtubule-associated proteins in GBM cell
lines have been described [13], and increasing immunor-
eactivity for the class III b-tubulin has been associated
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with an ascending gradient of malignancy [8]. Several
studies have explored the relationship between neuronal
antigens and the prognosis of gliomas. Varlet et al [6]
reported that a GBM subclass coexpressing glial fibril-
lary acidic protein and neurofilament protein had a
lower recurrence rate at the primary site and a better
prognosis. Furthermore, prognostic subclasses of high
grade gliomas have been identified, including a pro-
neural group expressing neuronal lineage markers that
was associated with longer survival than the other sub-
groups [3]. However, one recent study found that the
prognostic significance of neuronal marker expression
was limited to giant cell GBMs expressing two or more
neuronal markers, and that the expression of these mar-
kers was associated with shorter survival [5]. Thus, the
role of neuronal markers in human gliomas is still
unclear.
In this work, we investigated the expression and regu-
lation of four neuronal markers class III b-tubulin, neu-
rofilament protein (NFP), microtubule-associated
protein 2 (MAP2) and neuron-specific enolase (NSE) in
GBM cell lines and patient biopsies. Furthermore, we
quantified their expression under different culture con-
ditions. Since NSE was consistently upregulated under
different stress conditions we performed knock-down
experiments using NSE siRNA to see how this impacted
on glioma cell behavior. Finally, we correlated immuno-
positivity for NSE with patient survival using a panel of
glioma biopsies.
Methods
Cell culture
The human GBM cell line GaMG was established at the
Gade Institute, University of Bergen, Norway [14]; U87,
LN229, A172, U251 were purchased from the American
Tissue Culture Collection (ATCC; Manassas, VA, USA)
and cultured in DMEM (Sigma, St. Louis, MO) contain-
ing 10% fetal bovine serum, supplemented with NEAA,
100 U/ml Pen/Strep, 400 μM L-glutamine, all from
Cambrex (Cambrex, East Rutherford, NJ) and in stem
cell medium (SCM) consisting of Neurobasal Medium
(Invitrogen, Carlsbad, CA) supplemented with 20 μl/ml
B27 (Invitrogen), 10 μl/ml Glutamax (Invitrogen), 20
ng/ml EGF (Sigma), 20 ng/ml FGF2 (R&D Systems,
Minneapolis, MN) and 100 U/ml Pen/Strep (Cambrex).
Cells were also cultured in serum-free starvation med-
ium consisting of DMEM (Sigma) supplemented with
NEAA, 100 U/ml Pen/Strep and 400 μM L-glutamine
(Cambrex). The medium was changed every 2 days.
Patient biopsies
Patient biopsies were obtained from the Department of
Neurosurgery, Haukeland University Hospital, Bergen,
Norway. Collection of tumor biopsies and the
corresponding clinical data was appoved by the Regional
Ethical Committee (REK Vest). Prior to harvesting the
biopsies and clinical data, informed and written consent
was obtained from each patient that provided tissue.
Biopsy spheroids were prepared as previously described
[15], and monolayer cells from spheroids were cultured
both in DMEM medium and SCM.
Immunocytochemistry (ICC) and immunohistochemistry
(IHC)
Cell suspensions were plated on 12-mm cover slips
coated with poly-L-Lysine (50 μg/ml, 2 hr at 37°C). The
cells were fixed with 4% PFA for 10 min followed by 4
min permeabilization in 0.5% Triton-X at room tem-
perature, washed 4 times in PBS and then blocked with
protein block (PBS with 0.5% BSA) solution for 15 min.
Primary antibodies diluted in protein block solution
were incubated for 45 min at 37°C or overnight at 4°C.
After three washes with PBS, fluorescent conjugated sec-
ondary antibodies were applied in combination with
protein block solution for 45 min at 37°C. Cover slips
were washed four times with PBS, mounted with Vecta-
shield containing DAPI (Vector Laboratories, Burlin-
game, CA) or Prolong Gold antifade reagent with DAPI
(Invitrogen, Carlsbad, CA) and inspected under a Nikon
Eclipse TE2000-E fluorescence microscope (Nikon,
Tokyo, Japan).
The primary antibodies were diluted as follows:
chicken polyclonal anti-class III b-tubulin, 1:200
(Abcam, Cambridge, UK); mouse monoclonal anti-neu-
rofilament 70 kDa, 1:50 (Chemicon, Tamecula, CA,
USA); chicken polyclonal anti-MAP2, 1:100 (Abcam);
rabbit polyclonal anti-NSE, 1:100 (Abcam). The second-
ary antibodies were diluted as follows: goat anti-chicken
IgY-TR, 1:800 (Santa Cruz Biotechnology, CA, USA);
goat anti-rabbit IgG, 1:800 (Southern Biotech, Birming-
ham, Alabama, USA); goat anti-mouse IgG1, 1:200
(Southern Biotech).
For IHC, paraffin sections were rehydrated through a
procedure of 2 × 5 min in Xylene, 2 × 3 min in 100%
EtOH, 2 × 3 min in 96% EtOH and finally in ddH2O for
5 min. Heat induced epitope retrieval (HIER) was done
by heating sections to 95°C for 25 min in 10 mM Na-
Citrate buffer pH = 6. The sections were blocked with
peroxidase block buffer (DAKO, Denmark) for 5 min,
washed three times with TBS Tween 0.05% and blocked
with protein block (DAKO) for 30 min at room tem-
perature. Then the sections were incubated with the
rabbit anti-NSE antibody (Abcam) diluted 1:200 in buf-
fer (25 mM Tris-HCl, 75 mM NaCl, 1% BSA, pH 7.4)
overnight at 4°C, washed three times with TBS Tween
0.05% and incubated with HRP labeled polymer anti-
rabbit secondary antibody (DAKO) for 40 min at room
temperature. After 4 washes, the sections were
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developed with DAB+ (Dako) for 4 min, counterstained
with haematoxylin, dehydrated and mounted with Entel-
lan (Merck KGaA, Darmstadt, Germany). The sections
were examined and photographed using a light micro-
scope equipped with a digital camera (DXM1200,
Nikon, Japan).
For each slide, ten different microscopic fields were
selected and photomicrographs were captured at a mag-
nification of 40×. Immunoreactivity was scored as area
fractions calculated as the ratio of immunopositive area
to the total area of the microscopic field by an investiga-
tor as described before using a morphometry software
(NIS-Elements BR 3.2, Nikon, Japan) [16]. Immunostain-
ing intensity higher than average background was set as
pixel threshold for positive staining, which included
both nuclear and cytoplasmic stainings. The investigator
was blinded to the patient identities, with no prior
knowledge of clinical and pathological parameters. Only
after the scoring was completed, a clinician retrieved the
patient data from the journals at the hospital.
Immunoblots
Cultured cells were washed in PBS 2 × and subsequently
homogenized in lysis buffer (20 mM MOPS, 5 mM
EDTA, 2 mM EGTA, 30 mM NaF, 0.5% Triton X, 40
mM b-Glycerophosphate, 20 mM Na-Pyrophosphate, 1
mM Na-Orthovanadate, 3 mM Benzamidine, 5 uM Pep-
statin, 10 uM Leupeptin, 1 mM PMSF, pH 7.2) by soni-
cation 3 × 2 sec using Sonics Vibra Cell TM (Cole-
Parmer Instruments, Vernon Hills, IL). Whole lysate
was centrifuged for 30 min at 13,000 rpm and used for
the subsequent analysis. Protein (10-20 μg) was added
in each well and run on SDS-PAGE using NuPage pre-
cast Gels (Invitrogen). After blotting the nitrocellulose
membrane for 80 min and subsequent treatment with
blocking solution (TBS with 0.1% Tween, 5% milk pow-
der) for 1 hour at room temperature the membrane was
incubated overnight at 4°C in blocking solution contain-
ing chicken anti-class III b-tubulin (Abcam) diluted
1:25000, chicken anti-MAP2 (Abcam) diluted 1:100000,
rabbit anti-NSE (Abcam) diluted 1:1000, mouse anti-
NFL (Chemicon) diluted 1:1000 and rabbit anti-GAPDH
(Abcam) diluted 1:2000. The primary antibodies were
detected using a horseradish peroxidase (HRP)-conju-
gated rabbit anti-chicken secondary antibody diluted
1:3000 (Abcam), goat anti-rabbit secondary antibody
diluted 1:100000 (Beckman Coulter), goat anti-mouse
secondary antibody diluted 1:2500 (Santa Cruz Biotech-
nology). The Western blot was developed using Super-
signal West Femto Maximum Sensitivity Substrate
(Pierce Biotechnology, Rockford, IL) and detected with
Fuji LAS 3000 Imager (Fuji Photo Film, Tokyo, Japan).
Densitometric analysis was performed using Multi
Gauge V2.3 software (Fuji Photo Film, Tokyo, Japan)
and the levels of NSE were normalized to GAPDH
levels.
Isolation of total RNA
Total RNA was extracted using RNeasy Mini Kit (Qia-
gen GmbH, Hilden, Germany). The cell lines were
washed twice in PBS, added RLT buffer and scraped off
using a cell scraper. The remaining procedure was per-
formed according to the manufacturer’s instructions,
including treatment with DNase I (Qiagen GmbH, Hil-
den, Germany).
Real-time qPCR
250 ng total RNA was reverse transcribed in a total
volume of 10 μl using iScriptTM cDNA Synthesis Kit
(BioRad Laboratories, Hercules, CA) according to the
manufacturer’s instructions. The resulting cDNA reac-
tion mix was then diluted 20 times in ddH2O. Real time
qPCR was subsequently performed using iQ SYBR
Green Supermix (Bio-Rad Laboratories) according to the
manufacturer’s instructions, using 0.5 μl of the diluted
cDNA reaction mix in a total volume of 5 μl. The fol-
lowing parameters were used for the qPCR reaction:
initial denaturation at 95°C for 3 min, 45 cycles of 20
sec at 95°C, 20 sec at 58°C and 20 sec at 72°C using
Light Cycler 480 (Roche). Amplicon purity and size
were verified by melt curve analysis. Primers directed
against GAPDH were used as an internal control. Pri-
mers were designed using OligoPerfect™ Designer (Invi-
trogen). Human-specific primers were as follows:
Class III b-tubulin forward 5’-GCGAGATGTACGAA-
GACGAC-3’, reverse 5’-TTTAGACACTGCTGG
CTTCG-3’; NFL forward 5’-GAGGCAGCTGAAGAG-
GAAGA-3’, reverse 5’-AAGGAAATGGGGGTTCA
ATC-3’; NFM forward 5’-AAGGGATCCAGGAAG-
GAAGA-3’, reverse 5’-TGACAACGCCTTTCTCCTCT-
3’; NFH forward 5’-GAGGAACACCAAGTGGGAGA-3’,
reverse 5’-TTCTGGAAGCGAGAAAGGAA-3’; MAP2
forward 5’-CCAATGGATTCCCATACAGG-3’, reverse
5’-TCCTTGCAGACACCTCCTCT-3’; NSE forward 5’-
CTGATGCTGGAGTTGGATGG-3’, reverse 5’-CCATT-
GATCACGTTGAAGGC-3’; GAPDH forward 5’-GAGT-
CAACGGATTTGGTCGT-3’, reverse 5’-GACAAGC
TTCCCGTTCTCAG-3’. Negative controls were per-
formed without reverse transcriptase in the reaction. In
those cases, no amplification was found, ruling out con-
tamination of the RNA samples with genomic DNA
(data not shown). Fold changes were calculated using
the comparative CT (2-ΔΔCT) method.
RNA interference
ENO2 (NSE) silencing siRNA and nonsilencing control
siRNA were purchased from Ambion. Two validated
silencer select siRNAs targeting ENO2 at exon 7 or 9
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were used separately in the experiment. SiRNA duplex
(s4685, Ambion, Foster City, CA, USA) with sense sen-
quence: 5’-GGUGCAGAGGUCUACCAUATT-3’ and
antisense sequence: 5’-UAUGGUAGACCUCUG-
CACCTA-3’ targets exon 7. SiRNA duplex (s4684,
Ambion) with sense sequence: 5’-GUGACCAACC-
CAAAACGUATT-3’ and antisense sequence: 5’-UAC-
GUUUUGGGUUGGUCACTG-3’ targets exon 9. Cells
were transfected with siRNA oligonucleotides by using
Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s protocol.
Wounding experiment using Electric cell-substrate
impedance sensing (ECIS)
In ECIS, the cells are grown on the surface of small and
planar gold-film electrodes, then the AC impedance of
the cell-covered electrode is measured continuously at a
frequency of 64 kHz. Due to the insulating properties of
cell membranes, the impedance increases with increas-
ing coverage of the electrode until a confluent layer of
cells is established. 40000 A172 glioma cells were seeded
out in an 8E1W ECIS array (Applied Biophysics, Troy,
NY, USA), each well containing a single 250μM elec-
trode in the middle. Cells in four of the wells were trea-
ted with 20nM NSE siRNA, whereas two wells were
treated with scrambled siRNA at the same concentration
(both from Ambion, Foster City, CA, USA). Upon con-
fluence a high field current with frequency 48 kHz and
amplitude 5 was applied for 10 seconds which killed
cells overgrowing the electrode, creating “wounds” in
the wells devoid of cells. Successful wounding was con-
firmed with a rapid drop in impedance and absence of
cells on the electrode. Migration of surrounding glioma
cells into the area overlying the electrode could then be
monitored by measuring changes in impedance over
time. The migration was compared between control and
knockdown groups at the end of each experiment,
which was presented as the ratio of impedance before
and after the wounding until the end of each experi-
ment. The experiments were performed 3 times.
MTS assays and hypoxia, irradiation and temozolomide
(TMZ) treatment
MTS assays (Promega) were performed as previously
described [17]. Briefly A172 and U251 cells were seeded
into 96-well plates at a density of 2000 per well and
were subsequently treated with NSE or control siRNA.
18 hr after the preparation, the plates were incubated
under 0.5% oxygen in a hypoxia chamber (BioSpherix,
Lacona, New York, USA) or radiated with 4 Gy or trea-
ted with 10 μM (A172) or 50 μM (U251) TMZ (Tocris
Bioscience, UK) and cultured in a standard tissue cul-
ture incubator with 5% CO2 in air and 100% relative
humidity at 37°C. Each treatment condition was tested
in 30 wells, excluding wells at the edge. 5 or 6 days after
treatment, medium was removed and fresh medium
with MTS substrate (Promega) was added to each well.
Following 3 hr of incubation with MTS, the absorbance
at 490 nm was measured for each well with a scanning
multiwell spectrophotometer (Biochrom Asys UVM 340
Microplate Reader; Biochrom Ltd, UK). The experi-
ments were performed 3 times.
Patient data
The study population consisted of 28 consecutive glioma
patients admitted to the Department of Neurosurgery,
Haukeland University Hospital, Bergen, Norway,
between January 2005 and December 2007. These
patients were diagnosed with different glioma types and
patient characteristics and treatment parameters are
provided in Table 1.
Statistical analysis
Student’s t-test was performed using a 2-tailed distribu-
tion analysis. The duration of survival for patients with
gliomas was measured from the time of diagnosis to the
time of death or last follow-up. Survival data were ana-
lyzed using the log-rank test.
Results
Neuronal markers are expressed in both GBM cell lines
and GBM xenografts
We performed ICC and found that NSE, class III b-
tubulin and MAP2 were uniformly expressed in all the 5
GBM cell lines (A172, U251, U87, LN229 and GaMG,
figure 1A) and the 2 patient biopsies (pA and pB, figure
1B). In contrast, neurofilament protein was neither
detected in any of the cell lines nor the biopsies (data
not shown). Immunoreactivity for NSE was observed in
both the cytoplasm and the nuclear region, although it
was stronger in the nuclear area than in the cytoplasm.
The results were confirmed by Western blot (figure 1C).
GBM cells displayed immunoreactivity to different
MAP2 isoforms on the Western blot. The high-molecu-
lar weight form of MAP2 (hmw-MAP2) was mostly
found in U251, LN229 and pA, while high expression of
the low-molecular weight form (lmw-MAP2) was found
in A172. GaMG, U87 and pB were positive for both iso-
forms but showed relatively weaker signals.
NSE is upregulated under cellular stress conditions
Since real-time qPCR is a sensitive quantification
method, we used this method to quantify expression of
neuronal markers under different culture conditions.
We used cultures of the same cell lines/biopsies in
serum-containing DMEM medium in a standard tissue
culture incubator with 5% CO2 in air and 100% relative
humidity at 37°C as a reference. Furthermore, we
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evaluated the influence of both short-term (3 or 4 days)
and long-term (21 days) incubation in SCM and serum-
starvation medium on the expression of neuronal mar-
kers. After 3 days culture in SCM, NSE was downregu-
lated in 2 of the 5 GBM cell lines (fold change in LN229,
0.5 ± 0.05, p < 0.001; U87, 0.5 ± 0.04, p < 0.001) and
slightly upregulated in GaMG (1.4 ± 0.17, p = 0.041, fig-
ure 2A). After long-term culture in SCM, however, NSE
was significantly upregulated in all the GBM cell cultures
except for A172, in which NSE was downregulated (0.4 ±
0.12, p = 0.002, figure 2A). MAP2 was significantly down-
regulated in GaMG and LN229 after short-term culture
in SCM. After long-term culture it was significantly
downregulated in GaMG and pB while upregulated in pA
(data not shown). Class III b-tubulin was significantly
downregulated in GaMG and U87 while upregulated in
LN229 in long-term cultures in SCM (data not shown).
Since NSE was upregulated in SCM, we next investi-
gated NSE expression in short- and long term cultures in
serum-starvation medium (figure 2B). NSE was signifi-
cantly upregulated in all the GBM cell lines for both
short-term (fold change in GaMG, 2.3 ± 0.32, p = 0.016;
LN229, 1.3 ± 0.01, p < 0.001; U251, 3.2 ± 0.02, p < 0.001;
U87, 1.7 ± 0.15, p = 0.009) and long-term culture (fold
change in A172, 4.3 ± 1.32, p = 0.046; GaMG, 1.8 ± 0.08,
p < 0.001; LN229, 1.9 ± 0.12, p < 0.001; U251, 2.5 ± 0.45,
p = 0.014; U87, 1.9 ± 0.32, p = 0.032) except A172 cells
cultured for 4 days. Furthermore, NSE expression levels
showed only minor differences between short- and long
time cultures except for A172, in which NSE was strongly
upregulated only in the long-term culture. MAP2 was
upregulated in 4 of the 5 GBM cell lines in serum-starva-
tion medium (data not shown).
We also investigated the impact of hypoxia, which has
been established as an important factor in promoting
tumor aggressiveness and resistance to chemo- and
radiotherapy. Thus, we assessed the expression of neuro-
nal markers after 7 days incubation in 0.5% oxygen. NSE
was upregulated in all of the 5 GBM cell lines after 7
days in hypoxia, although only LN229 was significant (p
= 0.037, figure 2C). All the cells were cultured in serum-
containing DMEM medium. MAP2 was downregulated
in 4 of the 5 GBM cell lines after 7 days in hypoxia (fig-
ure 2C). In contrast to previous studies [18], class III b-
tubulin was significantly downregulated in all the cell
lines in hypoxia (p < 0.001) except for U87 (figure 2C).
To assess whether the increase of NSE transcripts in
gliomas in hypoxia leads to an increase of NSE at the pro-
tein level, we analyzed the expression of NSE in GBM cell
lines in hypoxia by western blot, normalized by the protein
content in normoxia (figure 2D and 2E). The results were
in keeping with the findings of real-time qPCR, showing a
consistent upregulation of NSE in hypoxia.
NSE knock-down reduce migration of glioma cells
Since NSE was consistently upregulated in different cel-
lular stress conditions, we hypothesized that it might
mediate tumor progression and resistance to various
treatment. In order to investigate the role of NSE in
glioma cells, we first confirmed knock-down of NSE in
glioma cells using synthetic NSE siRNA duplexes
(s4685, figure 3A). Knock-down was also observed with
another NSE siRNA duplexes (s4684, data not shown).
After treatment with NSE siRNA in A172 and U251 for
6 days, approximately 85-95% reduction of the NSE pro-
tein was observed on the Western blots.
Compared to control siRNA treatment, NSE siRNA
treatment resulted in a slight inhibition of glioma cell
growth measured by MTS assay, although this difference
was not significant (figure 3B). After treating A172 and
U251 with NSE siRNA for 7days, the growth of A172
Table 1 Glioma patients listed according to the NSE
expression level
Patients Diagnosis Age Gender Radiotherapy
(Gy)
Chemotherapy
1 GBM 58 M 60 T
2 Oligo (III) 59 M 54 T+PCV
3 Oligoastro
(II)
33 M 54 T
4 GBM 66 M 36 T
5 GBM 58 M 60 T
6 GBM 58 M 60 T
7 Astro (II) 49 M 54 T
8 Astro (II) 41 M - -
9 GBM 42 M 60 T
10 GBM 58 F 60 T
11 GBM 67 F 60 T
12 Astro (II) 33 M 54 T+PCV
13 GBM 38 M 90 T+PCV+GK
14 GBM 22 F 60 T+PCV
15 Oligo (III) 59 M 54 T+PCV
16 GBM 58 F 76 T
17 GBM 67 M 39 -
18 GBM 67 F 60 T
19 GBM 82 M 39 -
20 GBM 55 M 60 T
21 GBM 56 M 76 T
22 GBM 74 F 60 -
23 GBM 48 M 58 T
24 GBM 66 F 60 T
25 GBM 71 F - -
26 GBM 58 M 60 T+GL
27 GBM 64 M 60 T
28 Oligo (II) 49 M 54 T
Oligo, oligodendroglioma; Oligoastro, oligoastrocytoma; Astro, astrocytoma;
GBM, glioblastoma multiforme; F, female; M, male; T, temozolomide; PCV,
procarbazine, CCNU and vincristine; GK, gamma knife surgery; GL, glivec; -, no
treatment.
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was inhibited by 2% (p = 0.86), while U251 was inhib-
ited by 17% (p = 0.08). Furthermore, NSE siRNA treat-
ment decreased the migration of A172 cells into areas
devoid of cells following wounding experiment with
ECIS (figure 3C). Both of the treatment groups had
similar proliferation patterns before wounding by elec-
tric currents from electrodes underlying the monolayers
in the wells. After the wounding however, cells treated
with control siRNA migrated faster into the wounded
area overlying the electrode compared to cells treated
with NSE siRNA, demonstrated by a more rapid
increase in impedance with time. There was a significant
difference when comparing the ratio of impedance
before and after the wounding in the control and knock-
down groups (p = 0.038, figure 3D).
NSE knock-down reduce viability of glioma cells in
hypoxia and after irradiation or TMZ-treatment
Upon hypoxia treatment, NSE knockdown significantly
increased cell death both in the A172 and U251 glioma
cell lines as measured by MTS assay (figure 4A). After 6
days incubation in 0.5% oxygen, cell survival dropped to
67.1 ± 17.0% (p = 0.021) for A172 and 95.4 ± 1.7% (p =
0.004) for U251 in the control siRNA treatment group, in
the NSE siRNA treatment group cell survival dropped to
only 9.5 ± 1.8% (p < 0.001) for A172 and 63.6 ± 8.5% (p <
0.001) for U251. Furthermore, treatment with NSE siRNA
also potentiated the effect of 4 Gy irradiation and TMZ
treatment on cell death (figure 4B and 4C). After 4 Gy
irradiation, cell survival dropped to 84.3 ± 12.2% (p =
0.090, A172) and 97.0 ± 3.4% (p = 0.220, U251) in the con-
trol siRNA treatment group while in the NSE siRNA treat-
ment group cell survival dropped to only 1.6 ± 2.1% (p <
0.001, A172) and 47.2 ± 5.4% (p < 0.001, U251). After
TMZ treatment for 5 days, cell survival dropped to 66.4 ±
1.1% (p = 0.011, A172) and 96.3 ± 1.0% (p < 0.001, U251)
in the control siRNA treatment group, when pretreated
with NSE siRNA, cell survival dropped to only 9.6 ± 0.2%
(p < 0.001, A172) and 61.8 ± 4.0% (p < 0.001, U251).
NSE is expressed in a panel of human glioma biopsies
In order to assess the clinical relevance of our findings,
we performed IHC on a panel of 28 consecutively har-
vested biopsies from a cohort of glioma patients
A B
C
Figure 1 Expression of class III b-tubulin, MAP2 and NSE in GBM cells. (A, B) ICC for class III b-tubulin, MAP2 and NSE in GBM cell lines and
patient specimens. Staining intensity for NSE was stronger in the nuclei than in the cytoplasms. (C) Western blot for class III b-tubulin, MAP2 and
NSE in GBM cells. Different isoforms of MAP2 were expressed in different GBM cells. GAPDH was the loading control. High Mw MAP2, high
molecular MAP2; low Mw MAP2, low molecular MAP2. Scale bars: panel A = 20 μm, panel B = 50 μm.
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operated at our hospital. Gliomas of all grades stained
positive for NSE, although the staining intensity and
pattern varied markedly among patients. The mean area
fraction of immunopositivity was 5.7% for all gliomas,
varying between 0.3% and 30.7%. All tumors exhibited
both nuclear and cytoplasmic stainings (figure 5). NSE
staining was detected both in the vascular and necrotic
areas, however, increased cytoplasmic and nuclear stain-
ings were observed in pseudopalisading cells surround-
ing areas of necrosis (figure 5, p23).
High NSE expression is associated with shorter survival in
GBM patients
We obtained clinical data for the patients from whom
the biopsies were obtained, and found that median sur-
vival was 297 days for the GBM patients and 370 days
for the whole group of patients with both low and high
grade gliomas, with 4 patients being alive at the end of
the study. Next, we wanted to determine whether NSE
expression impacted on the survival outcome in the
patients diagnosed with GBM. Patients were ranked by
the area fraction staining positive for NSE in the biopsy
tumor sections and grouped accordingly, into two
equally sized groups of 10 patients with lower and 11
patients with higher NSE expression. Kaplan-Meier ana-
lysis demonstrated that GBM patients in the group with
high NSE expression lived significantly shorter (192 vs.
341 days, p = 0.04). Moreover, when excluding the 4
patients who did not receive the standard treatment of
54 Gy or more, the difference remained significant
between the 9 patients in the low expression group and
the 8 patients in the high expression group. Patients
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with low and high NSE expression had a median survi-
val of 385 and 232 days, respectively (p = 0.04, figure 6).
To rule out that this was caused by our specific cut-off,
we regrouped the patients so that the low expression
group contained 8 patients and the high expression
group contained 9 patients. However, we still found a
significantly longer survival for patients with low vs high
NSE expression (505 vs. 200 days, p = 0.01).
Discussion
Enolase is one of the glycolytic enzymes, and exists as a
dimer of two subunits. There are three kinds of subunits,
a-, b- and g- subunits. NSE is a gg- isozyme, also called
ENO2, and was reportedly only detected in neurons and
neuroendocrine cells under physiological conditions
[19,20]. Glycolysis is considered the main source of
energy for cancer cells [21]. Interestingly, astrocytic
tumor cells also stain positively for NSE [22], suggesting
that NSE-negative cells can acquire the ability to produce
NSE. This may reflect a form of adaptation to the
increased metabolic demands associated with a neoplastic
state [23]. Furthermore, others have reported that NSE
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has a neurotrophic and neuroprotective effect on neurons
in the CNS mediated by specific binding to the neuronal
surface [24]. Thus, NSE may also display non-glycolytic
functions, possibly acting as a survival factor. Concordant
with previously reported studies [22,25], we found that
NSE was aberrantly expressed in all the five GBM cell
lines and two patient biopsies, and was upregulated both
in serum-starvation medium and under hypoxic condi-
tions. Thus, NSE may play a role when glioma cells adjust
to a niche dominated by hypoxia and lack of nutrients as
tumors outgrow their blood supply. Interestingly, NSE
was also upregulated in long-term cultures in SCM.
Moreover, the involvement of NSE in glycolysis and
its role as a possible survival factor may also imply that
it represent a therapeutic target [26]. Indeed, knock-
down of NSE inhibited the proliferation by 17% in
U251, although not significantly (p = 0.08), NSE knock-
down also reduced the migration of A172 in the wound-
ing experiments. Furthermore, NSE knockdown
significantly reduced the viability of GBM cell lines in
hypoxia. Since hypoxia, has been linked to chemo- and
radioresistance [27], overall tumor aggressiveness, as
well as upregulation of NSE in our experiments, it also
suggests that expression levels of NSE may correlate
with prognosis in glioma patients. Notably, overexpres-
sion of ENO1, another enolase isozyme, in hepatocellu-
lar carcinoma [28] and head and neck cancer [29] has
been associated with poor clinical outcomes. In our
stuy, glioma patients displaying higher NSE expression
levels had a significantly shorter survival. Our findings
are in accordance with a previous study [5]. This may
result from the effect of NSE upon the response to
radiotherapy and chemotherapy, as we found that
knockdown of NSE sensitized these GBM cell lines to
irradiation and TMZ. It should be emphasized however,
that the mean age in the NSE low expression group was
lower than in the NSE high expression group (52.5 vs
64.5). Moreover, 4 patients in the NSE high expression
group did not receive chemotherapy. As such, our study
suffers from the same limitations as other retrospective
studies, with a biased selection of patients which influ-
ences the results. Therefore, controlled studies will be
needed to validate the clinical significance of NSE in a
greater number of glioma patients. In fact, the expres-
sion and prognostic value of NSE has been investigated
in several other tumors, including non small cell lung
cancer [30], breast cancer [31] and prostate cancer [32];
however, the expression of NSE in lung cancer and
breast cancer is associated with better survival, while
Figure 5 NSE expression in human glioma specimens . HE
staining and ICH staining for NSE on sections from patient
specimens. p1 and p3 belonged to the NSE low expression group
while p23 and p25 belonged to the NSE high expression group. p3
was oligoastrocytoma (grade II), p1, p23 and p25 were GBMs. NSE
staining existed both in the nucleus and cytoplasma. Arrows
represent pseudopalisading cells surrounding areas of necrosis. Scale
bars in the low magnification image (10×) = 100 μm, in the high
magnification image (40×) = 25 μm.
Figure 6 High NSE expression is associated with shorter
survival in GBM patients. Kaplan-Meier survival analysis of GBM
patients grouped by NSE expression. Among GBM patients receiving
standard radiotherapy treatment (n = 17) there was a significant
difference in survival (P = 0.04) between patients with low vs. high
NSE expression.
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NSE staining was associated with shorter survival [32] or
was of no practical value as an independent prognostic
indicator in patients with prostate cancer [33]. Vos et al
[34] also reported there was no prognostic value of
serum NSE levels in brain tumor patients.
Due to the cytoplasmic staining of NSE, it is difficult
to identify single positive cells in the field. For this rea-
son, we applied the area fraction of immunopositivity
method as previously described [16,35]. Previously, we
have used this method to obtain accurate estimates of
immunopositivity with cytoplasmic stainings [16].
In our study, both the hmw-MAP2 and lmw-MAP2
could be detected in GBM cells. However, different quan-
tities of the isoforms were expressed in different cell
lines. Interestingly, different expression levels were noted
under different culture conditions. Class III b-tubulin
was significantly downregulated in four GBM cell lines in
hypoxia, which contrasts previous studies. Previously,
increased expression of class III b-tubulin has been
observed in GBMs bordering geographic areas of
ischemic necrosis [8,36], the discrepancy between in vivo
and in vitro observations warrants further investigation.
Conclusions
This study shows that neuronal markers are aberrantly
expressed both in GBM cell lines and patient biopsies.
Furthermore, their expressions are altered by cellular
stress. NSE is consistently upregulated in different cellu-
lar stress conditions. NSE knockdown potentiates the
effect of chemo- and radiotherapy and expression levels
are inversely associated with survival. Further studies are
needed to investigate whether this can be explored
therapeutically.
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